Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
NeoGenomics, Inc. - Common Stock
(NQ:
NEO
)
13.78
+1.15 (+9.11%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NeoGenomics, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Where NeoGenomics Stands With Analysts
January 12, 2022
Over the past 3 months, 6 analysts have published their opinion on NeoGenomics (NASDAQ:
Via
Benzinga
NeoGenomics Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimbursement via the MolDX Program
January 11, 2022
FT. MYERS, FL / ACCESSWIRE / January 11, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024
January 10, 2022
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 10, 2021 – USA News Group – Nearly 10% of the estimated ~1.9 million new cancer cases in the USA will be diagnosed as...
Via
FinancialNewsMedia
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 28, 2021
Gainers China SXT Pharmaceuticals (NASDAQ:SXT...
Via
Benzinga
Analyst Ratings For NeoGenomics
December 07, 2021
Within the last quarter, NeoGenomics (NASDAQ:NEO) has observed the following...
Via
Benzinga
Where NeoGenomics Stands With Analysts
November 05, 2021
Over the past 3 months, 4 analysts have published their opinion on NeoGenomics (NASDAQ:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021
December 16, 2021
Upgrades According to B of A Securities, the prior rating for Generac Holdings Inc (NYSE:
Via
Benzinga
Recap: NeoGenomics Q3 Earnings
November 04, 2021
NeoGenomics (NASDAQ:NEO) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
NeoGenomics Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid Biopsy Subsidiary
December 13, 2021
FT MYERS, FL / ACCESSWIRE / December 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
NeoGenomics to Leverage Thermo Fisher Scientific’s Ion Torrent Genexus System in Upcoming Phase 1 Study for Myeloid Cancers
December 10, 2021
FT. MYERS, FL / ACCESSWIRE / December 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
The Implications Behind Genetron Health's Latest Earnings Report
December 08, 2021
Genetron Holdings Limited (NASDAQ: GTH) recently announced its latest fiscal report, elaborating its progress in the oncology genetic testing industry. The China-based company provides early tumor...
Via
Talk Markets
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 07, 2021
Gainers PLx Pharma (NASDAQ:PLXP) stock in...
Via
Benzinga
The Implications Behind Genetron Health's Latest Earnings Report
December 03, 2021
Image provided by Mentor Finance Genetron Holdings Limited (NASDAQ: GTH) recently announced its latest fiscal report, elaborating its progress in the oncology genetic testing...
Via
Benzinga
NeoGenomics To Participate In The Stephens Annual Investment Conference 2021
November 30, 2021
FT. MYERS, FL / ACCESSWIRE / November 30, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NASDAQ: NEO Shareholder Notice: Investigation over Potential Wrongdoing at NeoGenomics, Inc.
November 29, 2021
San Diego, CA -- (SBWIRE) -- 11/29/2021 -- An investigation on behalf of investors in NeoGenomics, Inc. (NASDAQ: NEO) shares over potential wrongdoing at NeoGenomics, Inc. was announced.
Via
SBWire
Exposures
COVID-19
NASDAQ:NEO Investor Notice: Investigation over Possible Securities Laws Violations by NeoGenomics, Inc.
November 10, 2021
San Diego, CA -- (SBWIRE) -- 11/10/2021 -- NeoGenomics, Inc. is under investigation concerning possible violations of securities laws in connection with certain financial statements.
Via
SBWire
Exposures
COVID-19
NeoGenomics Appoints Dave Daly to Its Board of Directors
November 10, 2021
FT. MYERS, FL / ACCESSWIRE / November 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
NeoGenomics, inc (NEO) Q3 2021 Earnings Call Transcript
November 06, 2021
NEO earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
NeoGenomics Reports Revenue of $121 Million in the Third Quarter
November 04, 2021
Third-Quarter 2021 Results and Highlights: - Consolidated revenue of $121 million, comprised of Clinical Services revenue of $102 million and Pharma Services revenue of $19 million - Consolidated...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Retirement
Exposures
COVID-19
Legal
Pension
NeoGenomics Announces Leadership Team Transition
November 04, 2021
FT. MYERS, FL / ACCESSWIRE / November 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
81 Biggest Movers From Yesterday
November 05, 2021
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8...
Via
Benzinga
55 Stocks Moving In Thursday's Mid-Day Session
November 04, 2021
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the...
Via
Benzinga
NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays
October 19, 2021
Two clinical studies including interventional RaDaR™ study FT. MYERS, FL / ACCESSWIRE / October 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Product Safety
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
November 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...
Via
Benzinga
Exposures
COVID-19
NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021
October 13, 2021
FT. MYERS, FL / ACCESSWIRE / October 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans...
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
COVID-19
Legal
Regulatory
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
October 31, 2021
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX:
Via
Benzinga
NeoGenomics Announces Board of Directors' Transition
October 12, 2021
Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the year FT....
From
NeoGenomics, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Retirement
Exposures
COVID-19
Legal
Pension
Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg
October 04, 2021
Guardant Health Inc (NASDAQ: GH) has decided not to pursue a potential acquisition of NeoGenomics Inc (NASDAQ: NEO), Bloomberg reported citing people...
Via
Benzinga
Why Guardant Health Is Down More Than 14% Friday
October 01, 2021
Investors aren't fans of an acquisition the diagnostics company is rumored to be considering.
Via
The Motley Fool
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.